Chinese biotech firms are transforming from generic producers into global innovators. An uptick in licensing deals, regulatory reform and a return of talent have combined to position China as a rising powerhouse in therapeutic R&D (research and development) and global drug licensing.
China-based drugmakers have been licensing out drug candidates to U.S. and European companies at a rapidly increasing rate. These are often early-stage therapeutics in oncology and immune disease. A recent example is Takeda Pharmaceutical Company’s $11.4 billion deal with China’s Innovent Biologics for ADCs and bispecifics, as of October 2025, which is intended to commercialize next-generation cancer therapies globally.
In the first quarter of 2025, assets sourced from China accounted for roughly 32% of global out-licensing deal value in biotech, up from roughly 21% in 2023-24. Western pharma companies are increasingly licensing from China because Chinese drug candidates offer speed, lower cost and a more appealing risk-return profile. That is challenging established Western drugmakers on cost and access.
The big picture
Two charts from The Economist, based on Citeline and LEK data, show the scale of the change. In active drug development by country of origin, the United States’ share has slipped since 2010, while China’s share grew from a thin sliver to a wide band over the same years.
The value of deals for drugs licensed from China has jumped as well. It was far higher from 2022 onward than in any earlier year shown, and 2024 was the largest year of all.
What to watch
Trump’s recent policies on the federal budget, including slashing funds for the NIH and implementing immigration restrictions (bans on H-1B, J and L visas), may contribute to scientific talent leaving the U.S. That would make the research ecosystem more uncertain in the future, and some major names are already shifting to Chinese firms.
Watch for more large-scale licensing and milestone deals between Chinese firms and Western partners, especially in oncology, bispecifics and ADCs.
There are open questions about how long this can last. One is how the boom would hold up in the long run under a continuing trade war, or an outright ban on pharmaceutical imports from China, with restrictions on Chinese biotech firms’ access to U.S. and European markets. The other is whether Chinese firms’ reliance on heavy government spending on biotech can prove sustainable.
Despite the speed and volume of China’s output, researchers warn that trial quality and ethical compliance in many cases lag global norms. Fewer than 1% of Chinese-trial publications in the past decade had undergone ethics review. As China’s biotech firms get more involved globally, close compliance with reviews and quality standards will become more of a challenge.